Target intelligence / Profile preview

NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2)

Target
NDUFA4L2
Molecular classification
Enzyme (respiratory chain enzyme), Electron transport chain complex subunit, Other (mitochondrial protein)
01

Overview

NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2), also known as COXFA4L2, is a nuclear-encoded mitochondrial protein that acts as a subunit associated with the electron transport chain, particularly modulating Complex I and IV function depending on the organismal context[1][2][7]. Although originally thought to be a part of Complex I, further research revealed tissue- and context-dependent association, notably as a hypoxia-inducible subunit in certain conditions. NDUFA4L2 attenuates mitochondrial oxygen consumption, likely as a protective adaptation to low oxygen by inhibiting electron transport and reducing reactive oxygen species production. It is overexpressed in several cancers (e.g., clear cell renal cell carcinoma) and is associated with poor outcomes, contributing to a metabolic shift favoring glycolysis over oxidative phosphorylation[11]. Pathogenic variants and dysregulation are linked to multisystem mitochondrial diseases, including Leigh disease, cardiomyopathy, and neurodevelopmental disorders[2][7].

Other names
NDUFA4L2COXFA4L2NUOMSMISTRHFLJ26118NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2NDUFA4 mitochondrial complex associated like 2cytochrome c oxidase hypoxia associated subunit FA4L2NADH-ubiquinone oxidoreductase MLRQ subunit homologmitochondrial stress response hypoxia
02

Biological functions

Electron transportOxidative phosphorylationRegulation of mitochondrial respiration (inhibition of complex I under hypoxia)Cellular adaptation to hypoxia
03

Disease associations

Cancer (especially clear cell renal cell carcinoma)Mitochondrial disease (e.g., Leigh disease)CardiomyopathyNeurodevelopmental delayOther disorders associated with mitochondrial dysfunction
04

Safety considerations

Potential toxicity from broad inhibition of mitochondrial function (e.g., risk of interfering with ATP synthesis and energy metabolism)Ubiquitous mitochondrial function raises risk of multisystem adverse effects if targeted indiscriminately
05

Biomarkers

Expression in tumors (overexpressed in clear cell renal cell carcinoma)Marker of mitochondrial hypoxic adaptation

Beyond the preview

Go deeper on NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call